Organon & Co. (OGN)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
As of 10:27AM EDT. Market open.
| Previous close | 19.50 |
| Open | 20.00 |
| Bid | 20.05 x 1200 |
| Ask | 20.06 x 800 |
| Day's range | 19.85 - 20.16 |
| 52-week range | 10.84 - 24.08 |
| Volume | |
| Avg. volume | 2,380,020 |
| Market cap | 5.125B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 4.99 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.12 (5.74%) |
| Ex-dividend date | 10 May 2024 |
| 1y target est | N/A |
- Business Wire
Organon Reports Results for the First Quarter Ended March 31, 2024
JERSEY CITY, N.J., May 02, 2024--Organon Reports Results for the First Quarter Ended March 31, 2024
- Business Wire
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
JERSEY CITY, N.J., April 08, 2024--Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Business Wire
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
SHANGHAI, China & JERSEY CITY, N.J., April 08, 2024--Organon and Henlius announce that Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoint
© 2024 Yahoo. All rights reserved.